54 Patients with ruptured gastrointestinal stromal tumours (GIST), a type of soft-tissue sarcoma, face a significantly worse prognosis compared to those with non-ruptured GISTs. A recent study investigated the effects of adjuvant imatinib, a cancer therapy known for targeting the genetic mutations in GIST, on the survival outcomes of these high-risk patients. Despite hopes for better results, extending imatinib treatment from one year to three years did not significantly improve survival rates for most patients with ruptured tumours. The findings were published in the British Journal of Cancer. GISTs, which can arise anywhere along the gastrointestinal tract, often rupture either spontaneously or during surgery, causing tumour cells to spill into the abdominal cavity. This is a severe complication, as it tends to lead to metastasis and recurrence, making treatment challenging. The Scandinavian Sarcoma Group XVIII/AIO trial provided the foundation for this analysis, including over 400 high-risk GIST patients who were randomly allocated to receive adjuvant imatinib for either one or three years post-surgery. The trial showed that patients with ruptured GISTs had a recurrence-free survival rate of only 21% after ten years, compared to 55% for patients with non-ruptured tumours. Similarly, overall survival for the ruptured group was 59%, while those without ruptures had a survival rate of 78%. These findings suggest that GIST rupture significantly impacts both recurrence and overall survival outcomes, confirming the high-risk nature of this complication. A key finding of the study was the lack of significant difference in survival outcomes between patients who received imatinib for one year versus those who received it for three years. This suggests that for most patients with ruptured GIST, the extended treatment duration might not provide a substantial additional benefit in preventing recurrence or improving survival. However, there was an exception in a subset of patients with a specific genetic mutation known as KIT exon 11 deletion. For these patients, three years of imatinib treatment resulted in a much higher ten-year overall survival rate (94%) compared to those who received only one year of treatment (54%). This highlights the importance of genetic profiling in guiding treatment decisions for GIST patients. The findings also raised questions about whether longer treatment durations beyond three years might be necessary for certain high-risk groups, such as those with ruptured tumours. While current guidelines recommend three years of adjuvant imatinib for high-risk patients, including those with GIST rupture, the study’s results point to a potential need for more extended treatment in specific cases. Earlier cohort studies and ongoing randomised trials may provide additional evidence on whether extending treatment to five years or even longer could be more beneficial for these patients. Despite the disappointing survival rates in the ruptured GIST cohort, the study did show that some patients, especially those with KIT exon 11 mutations, achieved long-term survival with appropriate treatment. This underlines the need for personalised approaches in managing high-risk GIST, taking into account factors like mutation type and tumour rupture status.